28 reports of this reaction
0.9% of all ACTIVATED CHARCOAL reports
#33 most reported adverse reaction
RHABDOMYOLYSIS is the #33 most commonly reported adverse reaction for ACTIVATED CHARCOAL, manufactured by Padagis US LLC. There are 28 FDA adverse event reports linking ACTIVATED CHARCOAL to RHABDOMYOLYSIS. This represents approximately 0.9% of all 3,053 adverse event reports for this drug.
ACTIVATED CHARCOAL has an overall safety score of 85 out of 100. Patients taking ACTIVATED CHARCOAL who experience rhabdomyolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHABDOMYOLYSIS is a less commonly reported adverse event for ACTIVATED CHARCOAL, but still significant enough to appear in the safety profile.
In addition to rhabdomyolysis, the following adverse reactions have been reported for ACTIVATED CHARCOAL:
The following drugs have also been linked to rhabdomyolysis in FDA adverse event reports:
RHABDOMYOLYSIS has been reported as an adverse event in 28 FDA reports for ACTIVATED CHARCOAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHABDOMYOLYSIS accounts for approximately 0.9% of all adverse event reports for ACTIVATED CHARCOAL, making it a notable side effect.
If you experience rhabdomyolysis while taking ACTIVATED CHARCOAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.